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Superoxide (O2−) contributes to the development of cardiovascular disease. Generation of O2− occurs in
both the intracellular and extracellular compartments. We hypothesized that the gene transfer of
cytosolic superoxide dismutase (SOD1) or extracellular SOD (SOD3) to blood vessels would differentially
protect against O2
−-mediated endothelial-dependent dysfunction. Aortic ring segments from New
Zealand rabbits were incubated with adenovirus (Ad) containing the gene for Escherichia coli β-
galactosidase, SOD1, or SOD3. Activity assays conﬁrmed functional overexpression of both SOD3 and
SOD1 isoforms in aorta 24 h following gene transfer. Histochemical staining for β-galactosidase showed
gene transfer occurred in the endothelium and adventitia. Next, vessels were prepared for measurement
of isometric tension in Kreb's buffer containing xanthine. After precontraction with phenylephrine,
xanthine oxidase impaired relaxation to the endothelium-dependent dilator acetylcholine (ACh, max
relaxation 3374% with XO vs. 6473% without XO, po0.05), whereas relaxation to the endothelium-
independent dilator sodium nitroprusside was unaffected. In the presence of XO, maximal relaxation to
ACh was improved in vessels incubated with AdSOD3 (5572%, po0.05 vs. control) but not AdSOD1
(3474%). We conclude that adenoviral-mediated gene transfer of SOD3, but not SOD1, protects the aorta
from xanthine/XO-mediated endothelial dysfunction. These data provide important insight into the
location and enzymatic source of O2− production in vascular disease.
Published by Elsevier B.V. Open access under CC BY license.Introduction
Reactive oxygen species (ROS) have an important role in
mediating vascular disease in hypertension, diabetes mellitus,
and atherosclerosis, as well as in acute conditions such as
hypoxia-reoxygenation. One clinically-relevant enzymatic source
of ROS is xanthine oxidase (XO). Circulating levels of XO are
increased with hypercholesterolemia [1,2]. Moreover, activity of
XO is elevated in human atherosclerotic lesions [3–5]. Infusion of a
XO inhibitor in humans with cardiovascular disease improves
vascular function [6]. The pathophysiologic effects of ROS causing
vascular dysfunction can occur through multiple mechanisms.
Superoxide anion (O2−) reacts with endothelium-derived nitric
oxide (NO) via a radical-radical reaction at a diffusion-limited rate
to generate peroxynitrite (ONOO−), a potent oxidant and mediatorine, 2269 CBRB, 285 Newton
+1 319 384 4524;
ler Jr.).
CC BY license.of vascular tissue injury [7]. Inactivation of NO impairs the ability
of vessels to relax normally [8]. Peroxynitrite can oxidize lipopro-
teins and damage lipid membranes. Oxidation of LDL in the vessel
wall by O2− can alter signal transduction and cause cytotoxicity
[9]. Excess levels of O2− increase platelet aggregation [10], and the
adhesion and migration of monocytes [11]. Cell proliferation and
cell death are also inﬂuenced by the cellular pro-oxidant state [12].
By activating metalloproteinases, O2− can also modulate matrix
degradation [13].
Perhaps the most important cellular mechanism by which to
protect against endothelial dysfunction involves the activity of
superoxide dismutases (SODs) in the vessel wall [14]. In cardio-
vascular disease, O2−-generating systems can result in both the
intracellular and extracellular generation of O2−. Of the two
copper–zinc containing SODs, one resides in the cytoplasm
(SOD1) and the second is extracellular and has an afﬁnity for
cell-surface heparin sulfate proteoglycans (SOD3) [15]. Adenoviral
delivery of SOD3 improves endothelial-dependent relaxation in
multiple disease states [16–19]. In contrast, gene transfer of SOD1
restores acetylcholine-dependent vasodilation response in diabetic
rabbits [20], whereas arterial relaxation in either hyperlipidemic
rabbits or rabbits treated with Ang-II is not improved [21,22].
A limitation of these studies is that O2− localization may be
intracellular and/or extracellular.
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cellular SOD in protecting against extracellular oxidant-induced
endothelial dysfunction. Our data demonstrate that adenoviral trans-
fer of SOD3 but not SOD1 improves vasomotor function following
exposure to xanthine/XO. We conclude that, to maintain bioavail-
ability of NO, SOD must be localized to the site of O2− production
rather than NO production, suggesting that the reaction of NO with
O2− occurs outside the cell.Methods
Animals and tissue preparation
All protocols were approved by the Animal Care and Use Commit-
tee at the University of Iowa. New Zealand white rabbits (n¼17, either
sex, 2.5–3.0 kg) were sacriﬁced with an overdose of pentobarbital and
the thoracic aorta immediately dissected and placed into ice cold
Kreb's bicarbonate buffer of the following composition of (in mM)
118.0 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 25.0 NaHCO3, 1.2 KH2PO4,
5.5 glucose, 0.0025 EDTA. The aorta was trimmed free of fat and
loosely adhering connective tissue, and cut into approximately 2.5 mm
wide ring segments. Vessel segments were incubated for two hours at
37 1C in 1.0 ml of Dulbecco's Modiﬁed Eagle Medium (DMEM) contain-
ing 0.1 ml of either replication deﬁcient adenovirus (5109 pfu/ml) or
phosphate buffered saline as described below. After two hours, the
vessel segments were transferred to DMEM containing 10% bovine
serum and placed in an incubator at 37 1C for 24 h.
Adenoviral-mediated gene transfer
Adenovirus (Ad) with CMV promoters used for this study were
obtained from the University of Iowa Gene Vector Core Facility
and include Adβgal for expression of the histochemical marker
β-galactosidase, AdSOD3 [21] for expression of the human extra-
cellular isoform of SOD, or AdSOD1 [23] for expression of the
human copper–zinc cytoplasmic isoform of SOD.
β-galactosidase activity assay
Rings were rinsed in phosphate buffered saline and ﬁxed in 2%
paraformaldehyde for 10 min. Segments were then stained in 1 mg/ml
of X-gal for 4 h at 37 1C. Tissue was further ﬁxed in 2% paraformalde-
hyde, imbedded in parafﬁn, and sectioned for histologic analysis.
SOD activity assay
SOD activity was measured by the method of NADPH oxidation
described by Paoletti and Mocali [24]. Because this method relies
on the oxidation of NADPH, it is less prone than other SOD assays
to interference by nonspeciﬁc reduction from cellular components.
Care was taken to insure specimens were free of blood. Aorta from
four different rabbits were combined for each intervention (con-
trol, Adβgal, AdSOD3, and AdSOD1) and homogenized with a
Dounce homogenizer in 50 mM KPO4 buffer (pH 7.4, 4 1C) contain-
ing anti-proteolytics (PMSF 1.0 mM, leupeptin 10 mg/ml, aprotinin
10 mg/ml, and pepstatin A 10 mg/ml, Sigma). The homogenate was
sonicated (ﬁve second burst times ﬁve) and centrifuged at 3000g
for ten minutes at 4 1C. Protein concentrations were determined
by the Lowry assay. The assay was performed in triplicate and
values averaged.
Isometric force measurement
Vasomotor reactivity of rabbit aorta was measured by determina-
tion of isometric force, 24 h after virus incubation. Ring segments weremounted in organ baths containing 10 ml of Kreb's buffer containing
xanthine (10−4 M) and catalase (500 U/ml) at 37 1C and continuously
gassed with 20% O2, 5% CO2, and 75% N2. Rings were stretched to an
optimal resting tension of 6 g as determined by repeated administra-
tion of KCl (75 mM). Vessels were equilibrated for 30 min and then
constricted twice with KCl (75 mM). After the segments were washed,
phenylephrine was added to achieve a tension of 50–100% of the
maximal contraction to KCl. Xanthine oxidase (XO, Sigma) was added
to the buffer for generation of O2− immediately prior to performing a
concentration response to the endothelium-dependent vasodilator
acetylcholine (ACh, 10−9–10−5 M) or the endothelium-independent
dilator sodium nitroprusside (SNP, 10−9–10−5 M). Although in some
vessels the addition of XO produced an increase in tension, this
increase was not signiﬁcant.
Based on our ﬁndings that 5 U/L of XO moderately impaired
relaxation to ACh without affecting the response to SNP, protocols
examining vasomotor responses following gene transfer were
performed with 5 U/L of XO. Only one concentration-dose response
curve was performed in each vessel. In this way, abnormalities in
relaxation could not be attributed to prior exposure to xanthine/XO.
Data analysis
Results are expressed as mean7standard error. For the ring
studies, data were obtained in duplicate for each intervention (control,
Adβgal, AdSOD3, and AdSOD1) and averaged such that n is equal to the
number of animals studied. Relaxations are the percent change from
the precontracted tension. Dilator responses are compared among
groups using a two factor repeatedmeasures ANOVAwith a Bonferroni
correction for multiple comparisons. A non-linear curve ﬁt (3 para-
meter with a Hill slope of 1.0) was used to determine the maximal and
EC50 relaxation (GraphPad Prism for Windows). Statistical signiﬁcance
was accepted if the null hypothesis was rejected at po0.05.Results and discussion
Effect of xanthine and xanthine oxidase on relaxation of aorta
We adapted a previously described model whereby incubation of
rabbit aortic ring segments in the presence of xanthine/XO impairs
endothelial-dependent relaxation [2]. After contraction with pheny-
lephrine (mean 7574%), increasing concentrations of the
endothelium-dependent dilator ACh produced a dose-dependent
relaxation (Fig. 1A). Addition of XO immediately prior to ACh
impaired relaxation. Our protocol for oxidant production was
designed such that generation of O2− occurred simultaneously with
ACh-induced release of NO. The maximal relaxation at 10−5 M ACh
was 8874% for control, 6177% for 1 U/L XO, 5078% for 5 U/L XO,
and 3275% for 10 U/L XO (po0.05 for each XO dose vs. control).
These results conﬁrmed that oxidants derived from XO mediate
vascular dysfunction in a concentration-dependent manner [2].
To conﬁrm that the observed impairment in dilation was endothe-
lium speciﬁc, we examined the relaxation of rabbit aorta to SNP.
Increasing concentrations of SNP produced a dose-dependent relaxa-
tion that was not affected by XO (Fig. 1B, relaxation at 10−5 M SNP is
10075% for control and 9774% for 5 U/L XO, p¼NS, n¼5). Based on
these data, 5 U/L of XO was used in subsequent protocols to produce
free radical-mediated impairment in relaxation.
Gene transfer of SOD to rabbit aorta increases SOD
expression and activity
Following gene transfer of β-galactosidase into vessel segments,
histochemical staining demonstrated β-galactosidase in the endothe-
lium and adventitia, indicative of efﬁcient gene transfer (Fig. 2A).
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Fig. 1. Xanthine oxidase-derived O2− impairs endothelial-dependent relaxation of rabbit aorta. (A) Dose-dependent relaxation to endothelium-dependent dilator
acetylcholine (ACh) in the absence or presence of increasing concentrations of XO as indicated. (B) Dose-dependent relaxation to endothelium-independent dilator sodium
nitroprusside (SNP) in the absence (black line) or presence (blue line) of 5 U/L XO. (n¼8–12) n po0.05 vs. control (no XO). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 2. Adenoviral-mediated gene transfer of SOD3 or SOD1 increases total SOD activity in rabbit aorta. (A) β-galactosidase activity as determined by X-gal staining of aortic
segments exposed to Adβgal. Blue staining denotes β-galactosidase activity, which limited to the endothelium and adventitial layers. (B) SOD activity in rabbit aorta one day
after adenoviral-mediated gene transfer of SOD1 or SOD3. Values are the mean of three assays performed on combined homogenate from four aortae. npo0.05 vs. Adβgal.
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the membrane and localize to the cytosol, respectively, when
expressed in vivo using these adenoviral constructs [17,25,26]. To
conﬁrm gene transfer of SOD3 and SOD1 produced functional
antioxidant protein in the vessel segments, SOD activity was deter-
mined by measuring NADPH oxidation. Total SOD activity in vessels
after transduction of SOD was approximately 4–6 times higher than
in non-transduced vessels (Fig. 2B).Effects of gene transfer of SOD on superoxide mediated
vasomotor dysfunction
We next examined the ability of gene transfer of SOD in aorta
to protect against oxidant-mediated abnormal relaxation. Follow-
ing gene transfer of β-galactosidase, the concentration-dependent
relaxation to ACh was impaired in the presence of XO (Fig. 3A).
Overexpression of SOD3 in the presence of XO restored relaxation
to control levels observed in the absence of XO. The maximal
relaxation of control vessels was markedly reduced by XO,
whereas gene transfer of SOD3 restored relaxation to ACh
(Fig. 3B). There was no difference in the EC50 between groups
(Fig. 3C). Bovine SOD added exogenously to the circulating buffer
prior to addition of XO improved relaxation to ACh as compared to
aorta in XO without SOD (Fig. 3A, C). This concentration of
exogenous SOD was sufﬁcient to inhibit O2− accumulation by
xanthine/XO detected by lucigenin-enhanced chemiluminescence
(Fig. 3D). In contrast to overexpression of SOD3, ACh-induced
relaxation of vessels overexpressing SOD1 was unchanged from
control vessels after XO (Fig. 4). As in Fig. 3, bovine SOD in the
presence of XO restored relaxation to ACh (Fig. 4). In all groups,
relaxation to the endothelium-independent dilator SNP was simi-
lar (Fig. 5). These data indicate that extracellular, but not cytosolic,SOD improved endothelium-dependent dilation during generation
of O2− by xanthine and XO.
In aorta incubated in xanthine/XO, gene transfer of SOD3 only
partially restored relaxation to ACh. Although greater vascular
levels of SOD, through increased transgene expression, may have
further improved ACh-induced dilation, this is unlikely since
vessels incubated in AdSOD3 relaxed similarly to vessels incubated
in exogenous SOD (500 U/ml). These observations suggest that the
inability of SOD to completely restore dilator responses of vessels
in xanthine/XO results from non-superoxide mediated mechanisms.
This hypothesis is consistent with studies showing hydrogen per-
oxide contributes to vascular injury caused by xanthine/XO [27].
The observation that gene transfer of SOD3 but not SOD1
improved relaxation of aorta during generation of O2− can be
explained by the cellular compartmentalization of the antioxi-
dants. Despite relatively similar SOD activity following gene
transfer of the two SOD isoforms, SOD1 is localized to the cytosol
and therefore has limited access to O2− generated in the extra-
cellular space [15]. In contrast, since SOD3 is primarily bound to
extracellular proteoglycans, it has greater access to O2− generated
by xanthine/XO. A limitation of this interpretation is based on the
concentration of XO at the endothelial surface via its reversible
interaction with glycosaminoglycans [28]. In this way, SOD3 may
displace XO and reduce its surface concentration, thereby limiting
endothelial dysfunction independent of its antioxidant effect. In
addition to XO, multiple other cellular enzyme systems have been
implicated in vascular disease, including NADPH oxidases, uncoupled
endothelial nitric oxide synthase (eNOS), mitochondrial respiratory
chain, and arachidonic acid metabolizing enzymes. Our model
speciﬁcally examines the ability of SOD1 vs. SOD3 in restoring
endothelial function in the presence of extracellular XO and do not
necessarily address the contribution of these other enzymes that
generate intracellular O2−.
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Fig. 3. Gene transfer of SOD3 protects aorta against XO-mediated vasomotor
dysfunction. Following gene transfer of SOD3, (A) dose-dependent relaxation to
ACh in the absence or presence of XO was determined. Gene transfer of
β-galactosidase serves as negative control and exogenously applied bovine SOD
(500 U/ml) serves as positive control. (n¼6–10) npo0.05 vs Adβgal without XO.
(B) Maximal relaxation to ACh based on non-linear curve ﬁt of data in (A). npo0.05
vs Adβgal without XO; +po0.05 Adβgal with XO. (C) EC50 relaxation to ACh based
on non-linear curve ﬁt of data in (A). (D) Lucigenin-enhanced chemiluminescence
of xanthine/XO in the presence or absence of bovine SOD (n¼3); po0.05.
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Fig. 4. Gene transfer of SOD1 does not protect against XO-mediated vasomotor
dysfunction. Following gene transfer of SOD1, (A) dose-dependent relaxation to
ACh in the absence or presence of XO was determined as described for Fig. 3.
npo0.05 vs Adβgal without XO. (B) Maximal relaxation and (C) EC50 to ACh based
on non-linear curve ﬁt of data in (A). npo0.05 vs Adβgal without XO;+po0.05
Adβgal+SOD+XO.
AdSOD1AdβgalAdβgalAdβgal AdSOD3
+SOD
+XO (5 U/L)
Fig. 5. Relaxation to SNP is preserved in the presence of xanthine-XO. Relaxation
response to 10−5 M SNP following gene transfer and treatment with XO. Gene
transfer of β-galactosidase serves as negative control and exogenously applied
bovine SOD (500 U/ml) serves as positive control. (n¼6–10).
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In summary, our data demonstrate that adenoviral mediated
gene transfer of either SOD3 or SOD1 to rabbit aorta increases
antioxidant activity, but only SOD3 protects against xanthine/XO-
induced endothelial dysfunction. Selective overexpression of SOD
to intracellular or extracellular compartments provides important
insights into the location and enzymatic source of O2− production
in vascular disease. Our data are particularly interesting whenconsidering that both XO and SOD3 can be internalized into the
cell via endocytosis [29,30]. The lack of protection with SOD1
provides strong evidence that the interaction of NO with O2−
occurs either outside of the cell, or potentially in an endocytic
vesicle. XO is implicated as the source of O2− in the vascular
E.L. Foresman, F.J. Miller Jr. / Redox Biology 1 (2013) 292–296296dysfunction associated with ischemia/reperfusion, diabetes, and
atherosclerosis [31–33], denoting the relevance of our studies with
xanthine/XO. Whereas oxypurinol and allopurinol improve vascu-
lar relaxation in humans [6], this strategy of inhibiting XO-derived
O2− is most effective in patients that are hyperuricemic [34]. By
contrast, SOD3 is protective in the pathogenesis of ischemia/
reperfusion injury, atherosclerosis, and hypertension [15]. Thus,
our data suggest that selective targeting of extracellular O2−, i.e.
with SOD3, may be broadly applicable to multiple cardiovascular
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